Shares of Carl Zeiss Meditec AG (OTCMKTS:CZMWY – Get Free Report) have been assigned an average rating of “Strong Sell” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell recommendation and two have assigned a hold recommendation to the company.
CZMWY has been the topic of a number of recent research reports. The Goldman Sachs Group downgraded Carl Zeiss Meditec from a “hold” rating to a “sell” rating in a research report on Monday, October 5th. Morgan Stanley assumed coverage on Carl Zeiss Meditec in a report on Wednesday, September 2nd. They issued an “underweight” rating for the company. Zacks Research upgraded Carl Zeiss Meditec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. UBS Group downgraded Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research report on Tuesday, August 11th. Finally, Barclays lowered Carl Zeiss Meditec from a “hold” rating to a “strong sell” rating in a report on Wednesday.
Get Our Latest Analysis on CZMWY
Carl Zeiss Meditec Stock Performance
OTCMKTS:CZMWY opened at $35.14 on Friday. The firm’s 50-day moving average is $36.75 and its 200-day moving average is $33.01. Carl Zeiss Meditec has a 52-week low of $26.65 and a 52-week high of $53.40.
Carl Zeiss Meditec Company Profile
Carl Zeiss Meditec AG is a medical technology company headquartered in Jena, Germany, and part of the ZEISS Group. The company develops, manufactures and distributes equipment and solutions for ophthalmology and microsurgery, serving hospitals, clinics and medical professionals worldwide. Its ophthalmic portfolio includes diagnostic systems for examining the eye, equipment for cataract and refractive surgery, surgical lasers, intraocular lenses and other related products. The company also supplies surgical microscopes, visualization systems and digital technologies used in neurosurgery, spine surgery, ear, nose and throat procedures, and other microsurgical specialties.
Featured Stories
- Five stocks we like better than Carl Zeiss Meditec
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.
